Bruce D. Cheson

Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Andrew J. Cowan, Krish Patel, Jakub Svoboda, Bijal Shah et autres

Background: For patients with the most common B-cell malignancies, assessment of minimal/measurable residual disease (MRD) is routinely incorporated into clinical trials to evaluate patient response and NCCN guidelines include recommendations for incorporation of MRD assessment into clinical practice for ALL, CLL, and …

us (code pays fourni par la source)

Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey E. Roeker, Christopher P. Fox, Toby A. Eyre, Danielle M. Brander et autres

AbstractPurpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact …

Supplementary Table 2 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg et autres

PDF file 54K, Supplementary Table 2: Distribution of Risk Groups in Intergroup Trial S0016 and in Selected Other Recent Major Trials of Advanced Follicular Lymphoma

Supplementary Table 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg et autres

PDF file 54K, Supplementary Table 1: Results of Multivariable Model of All Statistically Significant Factors for Both PFS and OS from Univariate Analyses

Supplementary Material from Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Ranjana H. Advani, Daniel Lebovic, Andy Chen, Mark W. Brunvand et autres

Supplementary Figure 1. Summary of study enrollment by dose level and disease cohort. All patients were evaluated for safety and anti-tumor activity. Supplementary Table 1. Enrollment. Supplementary Table 2. Treatment-emergent adverse events occurring in at least 10% of patients treated with pinatuzumab …

Data from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg et autres

Abstract Purpose: There is currently no consensus on optimal frontline therapy for patients with follicular lymphoma. We analyzed a phase III randomized intergroup trial comparing six cycles of CHOP-R (cyclophosphamide–Adriamycin–vincristine–prednisone (Oncovin)–rituximab) with six cycles of CHOP followed by iodine-131 tositumomab radioimmunotherapy (RIT) …

Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill et autres

Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.

Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill et autres

Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.

Supplementary Figure 1 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg et autres

PDF file 82K, Supplementary Figure 1: Wald Chi Square Analysis Defining Optimal Cutpoints for Lactate Dehydrogenase and Beta 2 Microglobulin Levels for Prognostic Model construction for PFS (S1A) or OS (S1B) for Patients Enrolled on Protocol S0016

Interim Update on the 'Watch' Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Krish Patel, Jakub Svoboda, Bijal Shah, Bruce D. Cheson et autres

Background: Clinical trials of investigational agents in B-cell malignancies have demonstrated significant improvements in efficacy over the past several years. Despite often high complete response rates, many patients still relapse. All relapses are caused by residual tumor cells, whether detectable by standard …

in, us (code pays fourni par la source)

Slaying the real giants in the war on chronic lymphocytic leukemia

Bruce D. Cheson

us (code pays fourni par la source)

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical)

Fabien Ricard, Sally F. Barrington, Ron Korn, Guenther Brueggenwerth et autres

The aim of this initiative was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for the consistent application of imaging assessment with the Lugano classification. Methods: Consensus was obtained through a …

us, gb, de, au, fr (code pays fourni par la source)